Highlight
- Comorbid cancer is prevalent among patients with cardio-kidney-metabolic (CKM) syndrome, affecting 7.3% of the studied population and associated with worse clinical outcomes.
- Finerenone, a non-steroidal mineralocorticoid receptor antagonist, consistently improves cardiovascular, kidney, and mortality outcomes in CKM patients regardless of cancer history.
- Patients with cancer history tend to have more advanced CKM stages and higher rates of adverse events, yet finerenone’s safety profile remains consistent.
- This pooled analysis clarifies that cancer comorbidity does not diminish the therapeutic benefits of finerenone in a high-risk multimorbid population.
Specialty calculators
For clinical reference; use professional judgment.

